GLP-1 and Thyroid Cancer: Understanding the Black Box Warning

May 24, 2026

GLP-1 and Thyroid Cancer: Understanding the Black Box Warning

By Dr. Onikepe Adegbola, MD PhD — Johns Hopkins-trained physician-scientist and founder of Casa de Sante

Key Takeaways

All GLP-1 medications carry a black box warning about medullary thyroid carcinoma (MTC). This is the most prominent warning the FDA can require — and it understandably causes anxiety.
The context: this warning is based on animal studies in RODENTS, where very high doses of GLP-1 caused thyroid C-cell tumors. The relevance to humans is uncertain because human thyroid C-cells have far fewer GLP-1 receptors than rodent C-cells.
Human data from millions of patients over 15+ years has NOT shown an increased risk of MTC. Multiple large epidemiological studies have found no signal.
However: the warning is appropriate as a precaution, and patients with a personal or family history of MTC or MEN2 syndrome should NOT use GLP-1 medications.

The Animal Studies

What Happened in Rats

Rodents exposed to liraglutide and semaglutide at doses far exceeding human doses developed C-cell hyperplasia and medullary thyroid carcinomas.
Rats have abundant GLP-1 receptors on their thyroid C-cells. GLP-1 stimulates these receptors → C-cell proliferation → tumors.
The effect was dose-dependent and time-dependent — higher doses and longer exposure increased risk.

Why It May Not Apply to Humans

Human thyroid C-cells express very LOW levels of GLP-1 receptors compared to rodent C-cells.
Studies on human thyroid tissue ex vivo (outside the body) show minimal calcitonin response to GLP-1 stimulation — suggesting the receptor pathway is much less active in humans.
Primate studies (more relevant to humans than rodent studies) showed no increase in C-cell tumors with GLP-1 treatment.

What the Human Data Shows

Large Epidemiological Studies

A 2023 meta-analysis of 45+ RCTs found no increased MTC risk with GLP-1 agonists.
The SUSTAIN and STEP trial programs (thousands of patients) reported no thyroid cancer signal.
Real-world pharmacovigilance data from millions of prescriptions: no confirmed increased MTC incidence above the background rate (MTC is very rare: ~0.2% of all thyroid cancers).

Important Nuances

MTC is extremely rare and very slow-growing. Even if there were a small increased risk, it would take decades of follow-up to detect.
GLP-1 medications have only been widely used since 2017 (semaglutide approval). We have ~8 years of mass-market data. A very small risk with a very long latency period could be missed.
This is why the black box warning remains: absence of evidence is not evidence of absence. The scientific uncertainty justifies continued precaution.

Who Should NOT Take GLP-1

Personal history of MTC: Any prior medullary thyroid carcinoma = absolute contraindication.
Family history of MTC: First-degree relative with MTC = absolute contraindication.
MEN2 syndrome: Multiple Endocrine Neoplasia type 2 includes MTC as a component. Genetic screening should be done if MEN2 is suspected.

What to Monitor

Calcitonin level: Not routinely recommended for all GLP-1 patients (would generate too many false positives). However, if you have a thyroid nodule or symptoms, calcitonin can help screen for MTC.
Neck symptoms to report: A new lump in the neck, persistent hoarseness, difficulty swallowing, or persistent neck pain. These are general thyroid red flags — not specific to GLP-1.
Regular thyroid checks: A neck exam at your annual physical is sufficient for most patients. Thyroid ultrasound only if indicated by symptoms or physical findings.

🛒 Thyroid + GLP-1 Nutritional Support

Daily Vitamin — Selenium and iodine are critical for thyroid function. Selenium is a cofactor for thyroid hormone conversion (T4→T3) and protects the thyroid gland from oxidative damage. Zinc supports thyroid hormone synthesis. A comprehensive vitamin ensures the thyroid has the micronutrients it needs to function optimally.
Whey Protein — Thyroid hormones are made from the amino acid tyrosine. Adequate protein intake ensures sufficient tyrosine for thyroid hormone production. This is especially important on GLP-1 when protein intake often drops below recommended levels.

Medical Disclaimer: This article is for educational purposes only. The black box warning on GLP-1 medications exists for good reason and should be discussed with your prescribing physician. Do not start or stop GLP-1 medications based on this article. If you have a family history of thyroid cancer, discuss this with your endocrinologist before starting GLP-1. Dr. Adegbola is the founder of Casa de Sante.

Back to blog

Keto. Paleo. No Digestive Triggers. Shop Now

No onion, no garlic – no pain. No gluten, no lactose – no bloat. Low FODMAP certified.

Stop worrying about what you can't eat and start enjoying what you can. No bloat, no pain, no problem.

Our gut friendly keto, paleo and low FODMAP certified products are gluten-free, lactose-free, soy free, no additives, preservatives or fillers and all natural for clean nutrition. Try them today and feel the difference!